Menu
Search
|

Menu

Close
X

Bellicum Pharmaceuticals Inc BLCM.OQ (NASDAQ Stock Exchange Global Market)

4.37 USD
-- (--)
As of Nov 14
chart
Previous Close 4.37
Open --
Volume --
3m Avg Volume 101,187
Today’s High --
Today’s Low --
52 Week High 10.37
52 Week Low 3.92
Shares Outstanding (mil) 43.36
Market Capitalization (mil) 182.55
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.33 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.827
FY17
-2.251
FY16
-2.569
FY15
-1.841
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
247.02
22.95
Price to Book (MRQ)
vs sector
1.97
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
38.66
15.47
LT Debt to Equity (MRQ)
vs sector
38.62
11.13
Return on Investment (TTM)
vs sector
-71.80
13.00
Return on Equity (TTM)
vs sector
-94.83
14.69

EXECUTIVE LEADERSHIP

James Brown
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Richard Fair
President, Chief Executive Officer, Interim Principal Financial Officer, Director, Since 2018
Salary: $494,532.00
Bonus: --
Alan Smith
Executive Vice President of Technical Operations, Since 2017
Salary: $357,773.00
Bonus: --
David Spencer
Chief Technology Officer, Since 2018
Salary: --
Bonus: --
Rosemary Williams
Interim Principal Accounting Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2130 W Holcombe Blvd Ste 800
HOUSTON   TX   77030-3307

Phone: +1832.3841100

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.

SPONSORED STORIES